50岁及以上成人带状疱疹疫苗的疗效、效果与安全性:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入27项研究共2 044 504例50岁及以上成人,比较减毒活疫苗与佐剂重组亚单位疫苗或安慰剂。网状Meta分析显示佐剂重组亚单位疫苗相较于减毒活疫苗和安慰剂在预防带状疱疹方面具有统计学优势,但注射部位不良事件风险更高。
要点
- 佐剂重组亚单位疫苗较减毒活疫苗可预防更多带状疱疹病例
- 佐剂重组亚单位疫苗注射部位不良事件风险高于减毒活疫苗和安慰剂
- 减毒活疫苗与安慰剂在实验室确诊带状疱疹发病率上无统计学显著差异
核心结论
- 使用佐剂重组亚单位疫苗可能比使用减毒活疫苗预防更多带状疱疹病例,但前者注射部位不良事件风险也更高。
研究设计与样本
- 系统综述结合贝叶斯Meta分析与网状Meta分析,检索Medline、Embase和Cochrane Library(建库至2017年1月)及灰色文献和纳入研究的参考文献。
- 纳入27项研究(其中22项随机对照试验),共2 044 504例50岁及以上成人,另有18份 companion reports。
主要发现
- 5项随机对照试验的网状Meta分析显示,减毒活疫苗与安慰剂在实验室确诊带状疱疹发病率上无统计学显著差异。
- 佐剂重组亚单位疫苗在预防带状疱疹方面统计学优于减毒活疫苗(疫苗效力85%,95%可信区间31%至98%)和安慰剂(94%,79%至98%)。
- 11项随机对照试验的网状Meta分析显示,佐剂重组亚单位疫苗注射部位不良事件多于减毒活疫苗(相对危险度1.79,95%可信区间1.05至2.34;风险差30%,95%可信区间2%至51%)和安慰剂(5.63,3.57至7.29;风险差53%,30%至73%)。
- 9项随机对照试验的网状Meta分析显示,佐剂重组亚单位疫苗全身不良事件多于安慰剂(相对危险度2.28,95%可信区间1.45至3.65;风险差20%,95%可信区间6%至40%)。
临床怎么用
- 对于50岁及以上成人,选择带状疱疹疫苗时需权衡佐剂重组亚单位疫苗更高的带状疱疹预防效力与其更高的注射部位不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy, effectiveness, and safety of the herpes zoster live attenuated vaccine with the herpes zoster adjuvant recombinant subunit vaccine or placebo for adults aged 50 and older. DESIGN: Systematic review with bayesian meta-analysis and network meta-analysis. DATA SOURCES: Medline, Embase, and Cochrane Library (inception to January 2017), grey literature, and reference lists of included studies. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Experimental, quasi-experimental, and observational studies that compared the live attenuated vaccine with the adjuvant recombinant subunit vaccine, placebo, or no vaccine in adults aged 50 and older. Relevant outcomes were incidence of herpes zoster (primary outcome), herpes zoster ophthalmicus, post-herpetic neuralgia, quality of life, adverse events, and death. RESULTS: 27 studies (22 randomised controlled trials) including 2 044 504 patients, along with 18 companion reports, were included after screening 2037 titles and abstracts, followed by 175 full text articles. Network meta-analysis of five randomised controlled trials found no statistically significant differences between the live attenuated vaccine and placebo for incidence of laboratory confirmed herpes zoster. The adjuvant recombinant subunit vaccine, however, was statistically superior to both the live attenuated vaccine (vaccine efficacy 85%, 95% credible interval 31% to 98%) and placebo (94%, 79% to 98%). Network meta-analysis of 11 randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more adverse events at injection sites than the live attenuated vaccine (relative risk 1.79, 95% credible interval 1.05 to 2.34; risk difference 30%, 95% credible interval 2% to 51%) and placebo (5.63, 3.57 to 7.29 and 53%, 30% to 73%, respectively). Network meta-analysis of nine randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more systemic adverse events than placebo (2.28, 1.45 to 3.65 and 20%, 6% to 40%, respectively). CONCLUSIONS: Using the adjuvant recombinant subunit vaccine might prevent more cases of herpes zoster than using the live attenuated vaccine, but the adjuvant recombinant subunit vaccine also carries a greater risk of adverse events at injection sites. PROTOCOL REGISTRATION: Prospero CRD42017056389.
引用
- Tricco AC, Zarin W, Cardoso R, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ. 2018. PMID: 30361202. doi:10.1136/bmj.k4029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。